SecBot SecBot

GRCE

Grace Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001444192 Biotech & Drug Discovery
$1.93 +0.01 (+0.52%)
Oct 23 4:00 PM ET · prev $1.92
Market cap
$40.3M
Nano cap
Median target
🔒 Subscribers only
1 year
−38.5%
from $3.14 · Oct 24
30 days
−10.6%
from $2.16
52-week range
$1.88–5.13
−62% from high · low Oct 19
Avg volume 20D
99.6K
Oct 1 spike 344.2K
Short interest
1.72M
≈8.2% of shares · −2.5%
Days to cover
19.0
at average volume
Insider net
+$615.9K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 1/5 ·Next Earnings date, Nov 16, 2026
Strongest BULLISH Two insiders at Grace Therapeutics, including the CEO and a 10% owner, made open-market purchases totaling…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $615.9K at an average $2.05. No open-market sales. Price is 6% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 5 added (0 new), 2 trimmed or exited.

  • Short sellersSTEADY

    Short interest −2.5% to 1.72M shares. 19.0 days to cover, ≈8.2% of shares.

  • TrendDOWNTREND

    8% below its 50-day average. New closing low $1.88 on Oct 19.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED349,740$793.9K
JANE STREET GROUP, LLCTRIM89,442$203.0K
UBS Group AGTRIM16,777$38.1K
BNP PARIBAS FINANCIAL MARKETSADD10,500$23.8K
MORGAN STANLEYDOUBLED9,448$21.4K
Arax Advisory PartnersDOUBLED1,000$2.3K
Federation des caisses Desjardins du QuebecDOUBLED41$93.00
Cerity Partners LLCDOUBLED849,055$3.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Apr 24, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Feb 18, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$615.9K
bought · 2 insiders
$0
sold · 0 insiders
−5.9%
vs their $2.05 cost
DateInsiderTypeValue
Oct 19, 2026
Opaleye Management Inc.
10%+ Owner
BUY$8.0K
Oct 16, 2026
Opaleye Management Inc.
10%+ Owner
BUY$68.8K
Oct 15, 2026
Opaleye Management Inc.
10%+ Owner
BUY$45.7K
Oct 14, 2026
Opaleye Management Inc.
10%+ Owner
BUY$21.7K
Oct 12, 2026
Opaleye Management Inc.
10%+ Owner
BUY$14.6K
Oct 9, 2026
Opaleye Management Inc.
10%+ Owner
BUY$10.9K
Oct 8, 2026
Opaleye Management Inc.
10%+ Owner
BUY$4.2K
Oct 5, 2026
Opaleye Management Inc.
10%+ Owner
BUY$3.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,721,067
shares short
-2.5%
vs prior settlement
19.0
days to cover
≈8.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Insider
Opaleye Management Inc. bought 4,256 shares
10%+ Owner @ $1.88 ($8.0K)
Oct 16, 2026 Insider
Opaleye Management Inc. bought 36,347 shares
10%+ Owner @ $1.89 ($68.8K)
Oct 15, 2026 Insider
Opaleye Management Inc. bought 23,485 shares
10%+ Owner @ $1.95 ($45.7K)
Sep 11, 2026 SEC
Two insiders at Grace Therapeutics, including the CEO and a 10% owner, made open-market purchases totaling $226K in a…
CLUSTER — Impact 6/10
Aug 13, 2026 SEC
Grace Therapeutics reported Q1 2027 results with a net loss of $15.8M ($0.91/share), significantly wider than the…
8-K — Impact 5/10
Aug 13, 2026 SEC
Grace Therapeutics reported a net loss of $15.8M for Q1 FY2027 (June 30, 2026), driven by a $13.5M impairment of IPR&D…
PRESS-RELEASE — Impact 5/10
Aug 13, 2026 Earnings
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Th
Aug 5, 2026 Press
Grace Therapeutics announced a ~$10M private placement (4,761,904 shares at $2.10/share) with new and existing…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 13, 2026
Earnings
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage…
Aug 6, 2026
Earnings date
GRCE Q1 2027 Earnings Scheduled — 2026-08-06
Aug 5, 2026
Contract
Grace Therapeutics Announces $10 Million Private Placement
Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend…
Jul 28, 2026
Press release
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data
Jun 23, 2026
Earnings date
GRCE Q4 2026 Earnings Scheduled — 2026-06-23

SecBot reports

10 filings · 2 press releases · 1 bullish · 4 bearish · 2 mixed · 3 neutral
All GRCE filing & press-release reports (12)